Close Menu

NEW YORK (GenomeWeb) – OncoCyte said after the close of the market on Tuesday that its second quarter net loss swelled year over year as it continues to advance its flagship liquid biopsy test toward commercialization.

For the three months ended June 30, the Alameda, California-based diagnostic developer incurred a net loss of $4.5 million, or $.12 per share, compared to a loss of $3.8 million, or $.13 per share, in the year-ago period. Analysts on average had expected a loss per share of $.09.

OncoCyte did not report any Q2 revenues, the same as in the year-ago quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

Apr
09
Sponsored by
Sophia Genetics

This webinar will present the utility of a personalized in silico analytical approach for the routine clinical diagnosis of channelopathies and cardiomyopathies. 

Apr
11
Sponsored by
Bionano Genomics

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.

Apr
17
Sponsored by
Isoplexis

This webinar will provide an overview of current biomarker strategies for guiding the use of combination checkpoint immunotherapies in blood cancers.